Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3

Details werden geladen...

https://endpoints.news/regenerons-phase-3-skin-cancer-miss-adds-to-mounting-failures-in-lag-3/

Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3

Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class.

BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test

https://endpoints.news/biomarins-rare-disease-therapy-shows-no-clinical-benefit-in-phase-3-test/

Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B - BioSpace

https://www.biospace.com/deals/regeneron-parabilis-set-out-to-create-new-drug-class-in-deal-worth-up-to-2-3b

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | The Manila Times

https://www.manilatimes.net/2026/05/17/tmt-newswire/globenewswire/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer/2345706

$https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/cullinan-therapeutics-to-present-initial-clinical-data-for-cln-978-in-treatment-refractory-rheumatoid-arthritis-and-systemic-lupus-erythematosus-at-eular-2026-congress/2346652$

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress | The Manila Times

https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/cullinan-therapeutics-to-present-initial-clinical-data-for-cln-978-in-treatment-refractory-rheumatoid-arthritis-and-systemic-lupus-erythematosus-at-eular-2026-congress/2346652

Login

Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3

Ähnliche Seiten

BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test

Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B - BioSpace

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | The Manila Times

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress | The Manila Times